Head to Head Analysis: Freedom Acquisition I (NASDAQ:FACT) vs. Mainz Biomed (NASDAQ:MYNZ)

Mainz Biomed (NASDAQ:MYNZ) and Freedom Acquisition I (NASDAQ:FACT) are both small-cap industrials companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Profitability

This table compares Mainz Biomed and Freedom Acquisition I’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Freedom Acquisition I	N/A	-31.14%	1.67%

Earnings and Valuation

This table compares Mainz Biomed and Freedom Acquisition I”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	18.88	-$21.65 million	($65.60)	-0.02
Freedom Acquisition I	N/A	N/A	$5.98 million	N/A	N/A

Freedom Acquisition I has lower revenue, but higher earnings than Mainz Biomed.

Institutional & Insider Ownership

55.8% of Freedom Acquisition I shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 0.2% of Freedom Acquisition I shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500. Comparatively, Freedom Acquisition I has a beta of 0.01, indicating that its stock price is 99% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Mainz Biomed and Freedom Acquisition I, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
Freedom Acquisition I	1	0	0	0	1.00

Summary

Mainz Biomed beats Freedom Acquisition I on 5 of the 8 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About Freedom Acquisition I

Freedom Acquisition I Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. Freedom Acquisition I Corp. was incorporated in 2020 and is based in New York, New York.